Movement Alert｜Alebund Pharmaceuticals-B Falls 5.4% in Regular Trading, Short-Term Profit-Taking After Prior Session Surge

Market Focus07-09

On July 9, Alebund Pharmaceuticals-B declined 5.4% in regular trading, trading at approximately 31.4 HKD/share, with turnover of HKD 2.91 million. The pullback follows the previous session's sharp rally of over 10%, which was driven by news that GIC and LAV collectively increased their holdings by over 1.32 million shares on the IPO date, involving approximately HKD 59 million in capital.

GIC acquired 872,000 shares at HKD 44.08 per share, raising its stake to 7.09%, while LAV purchased 450,000 shares at HKD 45.06, bringing its holding to 7.20%. Today's retreat is interpreted as short-term profit-taking after the institutional-buying-fueled surge. Since its June 29 listing at an IPO price of HKD 22.6, the stock has experienced extreme volatility, surging over 103% on its debut before undergoing multiple rounds of sharp swings.

The company is a biopharmaceutical firm focused on kidney diseases. Its core product AP301 is in the NDA sprint stage, with a China new drug application expected imminently and commercialization anticipated within 12 to 24 months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148369112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148369112","market":"us","top_or_hot":-1,"title":"Movement Alert｜Alebund Pharmaceuticals-B Falls 5.4% in Regular Trading, Short-Term Profit-Taking After Prior Session Surge","media":"Market Focus","content":"<p><p>On July 9, Alebund Pharmaceuticals-B declined 5.4% in regular trading, trading at approximately 31.4 HKD/share, with turnover of HKD 2.91 million. The pullback follows the previous session's sharp rally of over 10%, which was driven by news that GIC and LAV collectively increased their holdings by over 1.32 million shares on the IPO date, involving approximately HKD 59 million in capital.</p><p>GIC acquired 872,000 shares at HKD 44.08 per share, raising its stake to 7.09%, while LAV purchased 450,000 shares at HKD 45.06, bringing its holding to 7.20%. Today's retreat is interpreted as short-term profit-taking after the institutional-buying-fueled surge. Since its June 29 listing at an IPO price of HKD 22.6, the stock has experienced extreme volatility, surging over 103% on its debut before undergoing multiple rounds of sharp swings.</p><p>The company is a biopharmaceutical firm focused on kidney diseases. Its core product AP301 is in the NDA sprint stage, with a China new drug application expected imminently and commercialization anticipated within 12 to 24 months.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alebund Pharmaceuticals-B Falls 5.4% in Regular Trading, Short-Term Profit-Taking After Prior Session Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alebund Pharmaceuticals-B Falls 5.4% in Regular Trading, Short-Term Profit-Taking After Prior Session Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-09 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 9, Alebund Pharmaceuticals-B declined 5.4% in regular trading, trading at approximately 31.4 HKD/share, with turnover of HKD 2.91 million. The pullback follows the previous session's sharp rally of over 10%, which was driven by news that GIC and LAV collectively increased their holdings by over 1.32 million shares on the IPO date, involving approximately HKD 59 million in capital.</p><p>GIC acquired 872,000 shares at HKD 44.08 per share, raising its stake to 7.09%, while LAV purchased 450,000 shares at HKD 45.06, bringing its holding to 7.20%. Today's retreat is interpreted as short-term profit-taking after the institutional-buying-fueled surge. Since its June 29 listing at an IPO price of HKD 22.6, the stock has experienced extreme volatility, surging over 103% on its debut before undergoing multiple rounds of sharp swings.</p><p>The company is a biopharmaceutical firm focused on kidney diseases. Its core product AP301 is in the NDA sprint stage, with a China new drug application expected imminently and commercialization anticipated within 12 to 24 months.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"","article_id":"1148369112","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148369112","pubTimestamp":1783563702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 9, Alebund Pharmaceuticals-B declined 5.4% in regular trading, trading at approximately 31.4 HKD/share, with turnover of HKD 2.91 million. The pullback follows the previous session's sharp...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"异动警报|艾利邦制药-B常规交易跌5.4%前一交易日大涨后短线获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"On July 9, Alebund Pharmaceuticals-B declined 5.4% in regular trading, trading at approximately 31.4 HKD/share, with turnover of HKD 2.91 million. The pullback follows the previous session's sharp rally of over 10%, which was driven by news that GIC and LAV collectively increased their holdings by over 1.32 million shares on the IPO date, involving approximately HKD 59 million in capital.GIC acquired 872,000 shares at HKD 44.08 per share, raising its stake to 7.09%, while LAV purchased 450,000 shares at HKD 45.06, bringing its holding to 7.20%. Today's retreat is interpreted as short-term profit-taking after the institutional-buying-fueled surge. Since its June 29 listing at an IPO price of HKD 22.6, the stock has experienced extreme volatility, surging over 103% on its debut before undergoing multiple rounds of sharp swings.The company is a biopharmaceutical firm focused on kidney diseases. Its core product AP301 is in the NDA sprint stage, with a China new drug application expected imminently and commercialization anticipated within 12 to 24 months.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148369112","isCrawlerRequest":true}